Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

191results about How to "Inhibit cell proliferation" patented technology

Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof

The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
Owner:AMGEN FREMONT INC

Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof

The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
Owner:AMGEN FREMONT INC

Methods for preparing internally constrained peptides and peptidomimetics

The present invention relates to a method for preparing a peptide having a stable, internally constrained alpha-helical, beta-sheet / beta-turn, 310-helical, or pi-helical region and a method of stabilizing an alpha-helical, beta-sheet / beta-turn, 310-helical, or pi-helical region within a peptide structure. The resulting peptides and methods of using them are also disclosed.
Owner:NEW YORK UNIV

Use of benzimidazole analogs in the treatment of cell proliferation

InactiveUS20050197375A1Inhibit cell proliferationPreventing and treating and progressionBiocideOrganic chemistryBenzimidazole analogAnti-Carcinogenic Agents
The preferred embodiments are directed to small molecule inhibitors that are cellular proliferation inhibitors and thus are useful as anticancer agents. The small molecules have the general formulas that include a phenylbenzimidazole core ring.
Owner:AVANIR PHARMA

Compositions for treatment of cancer

ActiveUS20070238667A1Reduces SNCG-mediated resistanceInhibit cancer cell proliferationPeptide/protein ingredientsAntibody mimetics/scaffoldsAnkyrin Repeat ProteinCancer therapy
Synthetic peptides containing an ankyrin repeat-like motif or portion thereof and mimetics thereof which interact with synuclein-gamma (SNCG) and reduce SNCG-mediated resistance of SNCG-expressing cancer cells to treatment with anticancer drugs or inhibit tumorigenesis and cancer cell proliferation are provided. Compositions containing these peptides, portions thereof or mimetics thereof are also provided. Methods for use of these peptides or portions thereof, compositions, and mimetics thereof in potentiating efficacy of anticancer drugs, in particular microtubule inhibitors and hormonal cancer therapies, and in treating cancer are also provided.
Owner:SINGH VINAY K +1

Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound

The present invention provides a drug-eluting stent, wherein the stent is coated with one or more non-mucleotide P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Y12 receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y12 receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.
Owner:INSPIRE PHARMA

Cyclic peptide inhibitors of lysine-specific demethylase 1

Provided herein are cyclic peptide inhibitors of lysine-specific demethylase 1. These cyclic peptides have the potential to treat cancer, diabetes, cardiovascular disease, and neurological disorders.
Owner:MUSC FOUND FOR RES DEV

Modified oligonucleotides for telomerase inhibition

ActiveUS20050113325A1Superior cellular uptake propertyReduce Toxicity RiskBiocideGenetic material ingredientsTelomeraseLipid moiety
Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics.
Owner:GERON CORPORATION

Methods for treating cancer using anti-Wnt2 monoclonal antibodies and siRNA

This invention relates to methods of inhibiting the growth of cells, in particular cancer cells, that overexpress Wnt2. The methods comprise contacting the cell with an agent that binds to Wnt2 mRNA or Wnt2 protein, interferes with Wnt2 signaling or inhibits binding of the Wnt2 protein to another protein, such as a Frizzled receptor.
Owner:RGT UNIV OF CALIFORNIA

Macrocyclic lactone compounds and methods for their use

The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula:wherein R1, R2, R3, R5, R6 and R8 are each independently a member selected from the group consisting of H, C1-6 alkyl and OH; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2,—O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o— CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of:each of L2 and L3 are independently selected from the group consisting of:salts, hydrates, isomers, metabolites and prodrugs thereof.
Owner:ELIXIR MEDICAL CORP

Electrosurgical system and method for treating chronic wound tissue

An electrosurgical method for treating chronic wound tissue, comprising: positioning an active electrode in close proximity to the chronic wound, the active electrode being disposed on a distal end of an electrosurgical shaft; applying a high-frequency voltage potential difference across the active electrode and a return electrode sufficient to develop a high electric field intensity associated with a vapor layer proximate the active electrode and in close proximity to the wound tissue; and stimulating an expression of at least one healing mediator.
Owner:ARTHROCARE

Inhibitors for extracellular signal-regulated kinase docking domains and uses therefor

Provided herein are compounds and methods of using compounds that selectively inhibit binding to one or more docking domain regions of an extracellular signal-regulated kinase (ERK) to inhibit in a cell having an extracellular signal-regulated kinase activity. Such methods may be used to inhibit cell proliferation of a neoplastic cell, to treat a cancer and further may be used in conjunction with administration of an anticancer drug at a reduced dosage to treat a cancer with a concomitant reduction in toxicity to an individual receiving the treatment. Also provided is a method to design and screen for compounds to inhibit binding within the extracellular signal-regulated kinase docking domain region, using at least in part computer-aided drug design modeling.
Owner:SHAPIRO PAUL +1

Novel Fused Imidazole Derivative

ActiveUS20080103136A1High activityExcellent PLK inhibitory effectBiocideOrganic chemistryArylHydrogen atom
The present invention relates to a compound represented by the Formula [I]:Wherein:the A ring is a 5-membered aromatic heterocyclic group containing at least one hetero atom selected from a nitrogen atom, and the like; A1 and A2, are each a nitrogen atom, and the like; X2, X3, X4, and X5 are all carbon atoms, or alternatively any one of X2, X3, X4, and X5 is a nitrogen atom and the rest are all carbon atoms; R1 is a hydrogen atom, or the like; R2, R3, R4, and R5, are each a hydrogen atom, or the like; R6 and R6′, are each a hydrogen atom, and the like; R7 is an aryl group and the like; and R8 is an amino group or a hydroxy group,or a pharmaceutically acceptable salt or ester thereof.
Owner:MSD KK

Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism

The present invention provides methods for treating a variety of hyperproliferative and inflammatory mucocutaneous disorders, including, basal cell carcinoma, squamous cell carcinoma, psoriasis and atopic dermatitis, as well as skin irritation and disorders associated with skin aging and skin photodamage using inhibitors of cholesterol metabolism. The present invention further relates to the discovery that the combined use of several inhibitors of cholesterol metabolism produces synergistic effects. Furthermore, the present invention is directed to the use of inhibitors of cholesterol metabolism as excipients to enhance the effects of antiinflammatory drugs.
Owner:CELLEGY PHARMACEUTICALS INC

Methods for inhibiting tumor cell proliferation

The present invention provides methods, compounds, and pharmaceutical compositions for inhibiting tumor cell proliferation, by administering an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists to a subject.
Owner:SOUTHERN CALIFORNIA UNIV OF THE +1

Modulation of meiotic recombination

The invention provides methods of modifying the level of expression or functional activity of factors such as enzymes or other catalytic proteins or structural proteins, alone or in concert, to modify the frequency of meiotic homologous recombination involving the exchange of genetic information between non-sister chromatids from homologous maternal and paternal chromosomes. The steps at which modulation may occur include: homologous chromosome pairing, double-strand break formation; resection; strand invasion; branch migration; and resolution. Methods of plant and animal breeding are also provided that utilize the modulation of meiotic homologous recombination.
Owner:AGRI & AGRI FOOD +1

Janus kinase inhibitors and uses thereof

ActiveUS20170044111A1Decrease kinase activityReduced activityOrganic chemistryKinase activityMedicine
The present invention provides kinase inhibitors, such as compounds of Formula (I) and Formula (II). The compounds may covalently or non-covalently bind a kinase (e.g., Janus kinase 3 (JAK3)). Also provided are pharmaceutical compositions, kits, methods, and uses that involve the compounds for reducing the activity of a kinase and / or treating and / or preventing a condition associated with aberrant activity of a kinase (e.g., a proliferative disease, inflammatory disorder, autoimmune disorder, painful condition, and / or viral infection). (I) (II)
Owner:DANA FARBER CANCER INST INC

2-alkoxyestradiol analogs with antiproliferative and antimitotic activity

The application discloses novel 2-alkoxyestradiol analogs which exhibit anti-proliferative properties, and methods of making and using such compounds to inhibit undesired cell proliferation and tumor growth. Additionally, methods are disclosed of treating diseases associated with undesired angiogenesis and undesired proliferation, and methods of treating infectious disease wherein the infectious agent is particularly susceptible to inhibition by agents that disrupt microtubule organization and function.
Owner:SOUTHWEST FOUND FOR BIOMEDICAL RESE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products